MYOVIEW 230 micrograms KIT FOR RADIOPHARMACEUTICAL PREPARATION
How to use MYOVIEW 230 micrograms KIT FOR RADIOPHARMACEUTICAL PREPARATION
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the Patient
MYOVIEW 230 micrograms radiopharmaceutical preparation kit
Tetrofosmin
Read all of this leaflet carefully before this medicine is administered to you because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your nuclear medicine doctor who is supervising the procedure.
- If you experience side effects, consult your nuclear medicine doctor, even if they are not listed in this leaflet. See section 4.
Contents of theleaflet:
- What Myoview is and what it is used for
- What you need to know before using Myoview
- How to use Myoview
- Possible side effects
- Storage of Myoview
- Package contents and further information
1. What Myoview is and what it is used for
This medicine is for diagnostic use only. It is used only to identify
diseases.
Myoview belongs to a group of medicines called “radiopharmaceuticals”. It is administered before an examination and helps a special camera to see inside a part of the body.
- It contains the active ingredient called “tetrofosmin”. It is mixed with a radioactive component called “technetium-99m” before use.
- Once injected, it can be detected from outside the body by a special camera used in the examination.
- The examination can help your nuclear medicine doctor to check the functioning of the heart or to see heart lesions after a heart attack.
- Other people receive this medicine before an examination to examine lumps in the breasts.
Your nuclear medicine doctor or nurse will explain which part of your body will be examined.
Administration of Myoview involves receiving a small amount of radioactivity. Your doctor and nuclear medicine doctor have considered that the clinical benefit you will obtain from the procedure with the radiopharmaceutical outweighs the risk of radiation.
2. What you need to know before starting to use Myoview
Myoview must not be used:
- If you are allergic (hypersensitive) to Myoview or to any of the other components of Myoview. (Indicated in section 6).
- If you are pregnant or think you may be pregnant.
Do not use Myoview if you are in any of the above circumstances. If you are not sure, talk to your nuclear medicine doctor.
Warnings and precautions
Be especially careful with Myoview
Talk to your nuclear medicine doctor before using Myoview:
- The person to whom this medicine is administered is a child or adolescent.
- You have a delayed menstrual period. This could indicate that you are pregnant and, therefore, should not receive Myoview (see the section “Pregnancy and breastfeeding”).
- You are on a low-sodium diet.
- You are breastfeeding.
Before administration of Myoview you must:
Drink plenty of water before starting the procedure to urinate frequently during the first hours after its completion.
Children and adolescents
Safety and efficacy in patients under 18 years of age have not been established. Inform your nuclear medicine doctor if you are under 18 years of age.
Use of Myoview with other medicines
Tell your nuclear medicine doctor if you are taking or have recently taken or may have to take any other medicine, as some medicines may interfere with the interpretation of the images.
If you are going to undergo a heart examination, inform your nuclear medicine doctor if you are taking any of the following types of medicines. This is because they may affect the results of the examination:
- Betablockers, such as atenolol, bisoprolol or propranolol.
- Calcium antagonists, such as nifedipine, diltiazem or felodipine.
- Nitrates, such as glyceryl trinitrate, isosorbide mononitrate or isosorbide dinitrate.
- Any medicine for blood pressure, heart or heart failure.
If you are not sure if you are in any of the above circumstances, talk to your nuclear medicine doctor before using Myoview.
Use of Myoview with food and drinks
If you are going to undergo:
- A heart examination: you may be asked not to eat anything the night before the examination. Or you may be asked to have only a light breakfast on the morning of the examination day.
- A breast examination:you can eat and drink normally.
Pregnancy and breastfeeding
You must inform the nuclear medicine doctor before administration of Myoview if there is any possibility that you may be pregnant, if you have a delayed period or if you are breastfeeding.
In case of doubt, it is important that you consult your nuclear medicine doctor who supervises the procedure.
If you are pregnant
You must not receive Myoview if you are pregnant or think you may be pregnant. This is because it could affect your child.
The nuclear medicine doctor will only administer this medicine during pregnancy if the benefit is expected to outweigh the risk.
If you are breastfeeding
You must not breastfeed if you receive Myoview. This is because small amounts of radioactivity may pass into breast milk. If you are breastfeeding, the nuclear medicine doctor may wait until you finish breastfeeding before using Myoview. If it is not possible to wait, the doctor may ask you to:
- interrupt breastfeeding for 3 to 6 hours
- use formula feed for your child
- express breast milk and discard it
Please consult your nuclear medicine doctor when you can resume breastfeeding.
Driving and using machines
It is considered unlikely that Myoview will affect your ability to drive or use machines. Consult your doctor if you can drive or use machines after receiving Myoview.
Myoview contains sodium
This medicine contains 15 – 29 mg of sodium (main component of table/cooking salt) per reconstituted vial. This is equivalent to 0.7 – 1.4% of the maximum recommended daily sodium intake for an adult.
The use of Myoview involves exposure to “radioactivity”.
- Your nuclear medicine doctor will always consider the possible risks and benefits before administering the medicine.
Ask your nuclear medicine doctor if you have any questions.
3. How to use Myoview
There are strict rules about the use, handling, and disposal of radiopharmaceuticals. Myoview will only be used in special controlled areas. This product will only be handled and administered by trained and qualified personnel to use it safely. These people will take special care in the safe use of this product and will inform you of their actions.
The nuclear medicine doctor supervising the procedure will decide the amount of Myoview to be used in your case. This will be the minimum amount necessary to obtain the desired information.
Administration of Myoview and performance of the procedure
The usual dose for a heart examination is:
- A single injection after you have rested.
- A second injection (at least one hour later) in a situation of cardiac stress, for example, during or immediately after exercise.
The order of the two injections may be reversed for some people. Other people only need a single injection. In some cases, the nuclear medicine doctor may decide that it is better to administer the two injections on different days.
The usual dose for a breast examination is:
- A single injection.
Duration of the procedure
Your nuclear medicine doctor will inform you about the usual duration of the procedure.
After administration of Myoview, you must:
Urinate frequently to eliminate the product from your body
Your nuclear medicine doctor will inform you if you need to take special precautions after this medicine is administered. Consult your nuclear medicine doctor if you have any questions.
If you have been administered more Myoview than you should
Myoview is administered in a hospital or clinic by qualified personnel with specific training. Overdose is unlikely. However, in case of overdose, you will receive appropriate treatment.
If you have any further questions about the use of Myoview, ask the nuclear medicine doctor supervising the procedure.
4. Possible side effects
Like all medicines, Myoview can cause side effects, although not everybody gets them.
Administration of this radiopharmaceutical involves receiving a small amount of ionizing radiation with a very low risk of developing cancer and hereditary defects.
Serious side effects
If you experience an allergic reaction while you are in the hospital or clinic undergoing the examination, inform the nuclear medicine doctor immediately. The signs and symptoms may be:
Uncommon (may affect up to 1 in 100 people)
- Redness of the skin (flushing)
Rare (may affect up to 1 in 1,000 people)
- Rash
Frequency not known (frequency cannot be estimated from the available data)
- itching, redness or hives
- swelling of the face, local swelling
- difficulty breathing, wheezing, throat tightness, cough
In more severe cases (severe allergic reactions or anaphylaxis), the reactions may consist of:
- fainting (loss of consciousness), feeling of instability or dizziness.
If you experience any of the above side effects after leaving the hospital or clinic, go directly to the emergency department of the nearest hospital.
Other side effects are
Uncommon (may affect up to 1 in 100 people)
- alteration of taste, such as metallic taste
- unpleasant feeling of heat that starts at the injection site
- vomiting
Rare (may affect up to 1 in 1,000 people)
- alteration of smell
- visual disturbance
- abdominal pain, discomfort (nausea), burning sensation in the mouth
Frequency not known (frequency cannot be estimated from the available data)
- headache, dizziness
- palpitations, chest pain
- fever
- increase in white blood cell count (in some types of blood tests)
Reporting of side effects:
If you experience any side effects, consult your doctor, even if they are not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Myoview
You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in suitable facilities. The storage of radiopharmaceuticals will be carried out in accordance with national regulations on radioactive materials.
Hospital staff will ensure that the product is stored and dispensed correctly. Do not use Myoview after the expiry date stated on the label.
The following information is intended only for specialists.
Keep Myoview out of the reach and sight of children.
Do not use Myoview after the expiry date stated on the label, after CAD. Store the product in the refrigerator at 2-8 ºC. Keep in the original package to protect from light.
The chemical and physical stability of the reconstituted injectable solution has been demonstrated for 12 hours at 2-25 ºC. Store the reconstituted product below 25 ºC. Do not freeze.
6. Package contents and further information
The following information is intended exclusively for medical professionals or healthcare professionals.
Composition of Myoview
- The active ingredient is tetrofosmin. Each vial of Myoview contains 230 micrograms of tetrofosmin.
- The other components are tin(II) chloride dihydrate, sodium sulfoisophthalate, sodium D-gluconate, and sodium bicarbonate.
Appearance of the product and package contents
Myoview is a radiopharmaceutical preparation kit that is supplied in a colorless glass vial containing a powder for injectable solution. The packages are available in sizes of 2 or 5 vials; not all package sizes may be marketed.
Marketing authorization holder and manufacturer:
Marketing authorization holder
GE HEALTHCARE BIO-SCIENCES, S.A.U.
C/ Gobelas, 35-37, La Florida
28023 Madrid, Spain
Manufacturer
GE Healthcare AS
Nycoveien, 1
NO-0485 Oslo
Norway
Date of last revision of this leaflet: 06/2023
Other sources of information
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.es/
Myoview is a trademark of GE Healthcare.
GE and the GE monogram are trademarks of General Electric Company.
____________________________________________________________________________
This information is intended only for doctors or healthcare professionals:
The complete technical data sheet of Myoview is included in the product packaging, as a separate section of this leaflet, in order to provide healthcare professionals with scientific and practical information on the administration and use of this radiopharmaceutical.
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to MYOVIEW 230 micrograms KIT FOR RADIOPHARMACEUTICAL PREPARATIONDosage form: RADIOPHARMACEUTICAL, 0.23 mgActive substance: technetium (99mTc) tetrofosminManufacturer: Rotop Pharmaka GmbhPrescription requiredDosage form: RADIOPHARMACEUTICAL, 1 mgActive substance: technetium (99mTc) sestamibiManufacturer: Narodowe Centrum Badan JadrowychPrescription requiredDosage form: RADIOPHARMACEUTICAL, 0.5 MG Methoxy-isobutyl-isonitrile-copper(I)-tetraActive substance: technetium (99mTc) sestamibiManufacturer: Radiopharmacy Laboratorium Kft.Prescription required
Online doctors for MYOVIEW 230 micrograms KIT FOR RADIOPHARMACEUTICAL PREPARATION
Discuss questions about MYOVIEW 230 micrograms KIT FOR RADIOPHARMACEUTICAL PREPARATION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions